| scholarly article | Q13442814 |
| P2093 | author name string | Ralph A Reisfeld | |
| Markus Loeffler | |||
| Jörg A Krüger | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5027-5030 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. | |
| P478 | volume | 65 |
| Q92071397 | Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma |
| Q37283379 | Cellular immunotherapy for ovarian cancer |
| Q28468315 | Chemophototherapy: An Emerging Treatment Option for Solid Tumors |
| Q34909777 | Chemotherapy and tumor immunity: an unexpected collaboration |
| Q38062792 | Clinical opportunities and challenges in targeting tumour dormancy |
| Q36543803 | Clinical results of vaccine therapy for cancer: learning from history for improving the future |
| Q36253709 | Combination approaches to potentiate immune response after photodynamic therapy for cancer |
| Q37197377 | Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory t cells in the granulomatous lesions |
| Q37832967 | Contribution of the immune system to the chemotherapeutic response. |
| Q83337287 | Cyclophosphamide enhances the immunosuppressive action of its own active metabolites |
| Q45712444 | Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma |
| Q54517461 | Cyclophosphamide promotes pulmonary metastasis on mouse lung adenocarcinoma. |
| Q38348844 | Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No? |
| Q38115968 | Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer |
| Q42701148 | Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy |
| Q35238258 | Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus |
| Q35051306 | Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state |
| Q36174037 | Mesenchymal stem cells: a double-edged sword in regulating immune responses |
| Q36360811 | Metabolism and transport of oxazaphosphorines and the clinical implications |
| Q47103586 | Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key. |
| Q38006448 | Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package |
| Q39290128 | Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo |
| Q37763502 | Metronomic chemotherapy: new rationale for new directions |
| Q37236004 | Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma |
| Q33918981 | Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts |
| Q39695611 | Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma |
| Q86328955 | Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer |
| Q50576205 | Neem leaf glycoprotein generates superior tumor specific central memory CD8+ T cells than cyclophosphamide that averts post-surgery solid sarcoma recurrence. |
| Q36535358 | Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. |
| Q42683580 | Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen |
| Q36684496 | Roadmap to a better therapeutic tumor vaccine |
| Q34697795 | Stimulation of anti-tumor immunity by photodynamic therapy |
| Q39365796 | Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents. |
| Q36350565 | Towards a therapeutic breast cancer vaccine: the next steps |
| Q36728805 | Use of attenuated bacteria as delivery vectors for DNA vaccines |
| Q39413633 | VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. |
Search more.